Summit Therapeutics (NASDAQ: SMMT) is trading up 80% in pre-open trade after ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Momentum Movers Trader Talk

Summit Therapeutics (SMMT) PT Raised to $30 at Needham & Company Amid Sarepta DealOctober 4, 2016 1:38 PM Oppenheimer Keeps Summit Therapeutics (SMMT) at 'Outperform' Amid New DMD Deal (SRPT)October 4, 2016 9:31 AM Baird Remains Positive on Sarepta (SRPT) Amid New DMD Deal; Affirms at 'Outperform'October 4, 2016 9:13 AM Sarepta (SRPT) Deal with Summit Removes a Competitive Threat and Increases its Takeover Attractiveness - RBCOctober 4, 2016 9:01 AM Deal Positive for Sarepta (SRPT), Summit (SMMT) and DMD Community - OppenheimerOctober 4, 2016 8:44 AM Sarepta (SRPT), Summit Therapeutics (SMMT) Enter Licensing Agreement for Utrophin Modulator PipelineOctober 4, 2016 7:02 AM Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of DucOctober 4, 2016 7:01 AM Sarepta Therapeutics and Summit Enter Into Exclusive License and Collaboration Agreement for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular DystrophyOctober 4, 2016 7:00 AM